Baxter International (BAX) FY2025 10-K Annual Report
Baxter International (BAX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Baxter International FY2025 10-K Analysis
Business Overview
- • Core business model: diversified healthcare products including IV solutions, infusion systems, parenteral nutrition, surgical and respiratory devices
- • New segment structure: three reportable segments as of Q3 2023 — Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals
- • Strategic shift: completed sale of Kidney Care business for $3.71B net proceeds and BioPharma Solutions for $3.96B, focusing on streamlined operations
- • Debt reduction: repaid $3.81B legacy debt primarily from Kidney Care sale and additional repayments using BioPharma sale proceeds
- • Geographic footprint: products manufactured in 20+ countries and sold in 100+ countries, reinforcing global healthcare access
Management Discussion & Analysis
- • Kidney Care business sold for $3.80B cash, net after-tax proceeds approx. $3.3B completed Jan 31, 2025
- • Legacy indebtedness of $3.81B repaid in 2025, excluding $2.00B repaid from new notes offering
- • Kidney Care segment results reported as discontinued operations, prior periods restated accordingly
- • Cost restructuring initiated due to dis-synergies from reduced company size post-sale
- • No explicit revenue, profitability, or forward guidance disclosed in provided text
Risk Factors
- • FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations
- • Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified
- • Supply chain disruptions including manufacturing, sterilization, and distribution difficulties causing product availability risks
- • Competition risk from technology advances and changing consumer preferences potentially impairing new product monetization
- • Significant indebtedness requiring substantial cash flow allocation for debt service, limiting growth strategy and R&D investments
Baxter International FY2025 Key Financial MetricsXBRL
Revenue
$11.2B
▲ +5.7% YoY
Net Income
-$957M
▼ -47.5% YoY
Gross Margin
30.1%
▼ -741bp YoY
Operating Margin
-2.7%
▼ -287bp YoY
Net Margin
-8.5%
▼ -241bp YoY
ROE
-15.6%
▼ -629bp YoY
Total Assets
$20.1B
▼ -22.2% YoY
EPS (Diluted)
$-1.87
▼ -47.2% YoY
Operating Cash Flow
$845M
▼ -17.1% YoY
Source: XBRL data from Baxter International FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Baxter International
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.